Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update
01:00pm, Wednesday, 04'th Mar 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced i
H.C. Wainwright Reiterates Buy on Navidea Biopharmaceutical, Raises Price Target to $4
12:00am, Monday, 02'nd Mar 2020Insider Buying: John Scott Just Spent US$2.0m On Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Shares
01:42pm, Friday, 21'st Feb 2020
Those following along with Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) will no doubt be intrigued by the recent...
Navidea Biopharma Reports Regained NYSE American Compliance
12:00am, Friday, 14'th Feb 2020Investors Who Bought Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shares Five Years Ago Are Now Down 97%
02:20pm, Wednesday, 12'th Feb 2020
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) shareholders will doubtless be very grateful to see the share price up...
Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York
12:00am, Monday, 30'th Dec 2019Cyclopharm (ASX:CYC) announces expansion of PET diagnostics business opportunities
04:10am, Monday, 23'rd Dec 2019
23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostics business opportuni
